Clinical trial
Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis
NCT00163852 · Bayside Health, Other · Unknown status
Key facts
| NCT number | NCT00163852 |
|---|---|
| Title | Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis |
| Official title | Salt Replacement for Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis |
| Lead sponsor | Bayside Health, Other |
| Collaborators | National Health and Medical Research Council, Australia Monash University Cystic Fibrosis Federation Australia |
| Status | Unknown status |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Normal saline IV, salt tablets |
| Enrollment | 40 |
| Start date | Feb 1, 2004 |
| Completion | Feb 1, 2006 |
| First posted | Sep 14, 2005 |
| Last update posted | Sep 14, 2005 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: